Literature DB >> 21271316

The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation.

Sunday A Shoyele1, Neeraj Sivadas, Sally-Ann Cryan.   

Abstract

Pulmonary delivery of therapeutic peptides and proteins has many advantages including high relative bioavailability, rapid systemic absorption and onset of action and a non-invasive mode of administration which improves patient compliance. In this study, we investigated the effect of spray-drying (SD) and spray freeze-drying processes on the stability and aerosol performance of parathyroid hormone (PTH) (1-34) microparticles. In this study, the stabilisation effect of trehalose (a non-reducing sugar) and Brij 97 (a non-ionic surfactant) on spray-dried PTH particles was assessed using analytical techniques including circular dichroism (CD), fluorescence spectroscopy, modulated differential scanning calorimetry and an in vitro bioactivity assay. Physical characterisation also included electron microscopy, tap density measurement and laser light diffraction. The aerosol aerodynamic performance of the formulations was assessed using the Andersen cascade impactor. Based on these studies, a formulation for spray freeze-drying was selected and the effects of the two particle engineering techniques on the biophysical stability and aerosol performance of the resulting powders was determined. CD, fluorescence spectroscopy and bioactivity data suggest that trehalose when used alone as a stabilising excipient produces a superior stabilising effect than when used in combination with a non-ionic surfactant. This highlights the utility of CD and fluorescence spectroscopy studies for the prediction of protein bioactivity post-processing. Therefore, a method and formulation suitable for the preparation of PTH as a dry powder was developed based on spray-drying PTH with trehalose as a stabiliser with the bioactivity of SD PTH containing trehalose being equivalent to that of unprocessed PTH.
© 2011 American Association of Pharmaceutical Scientists

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21271316      PMCID: PMC3066375          DOI: 10.1208/s12249-011-9585-2

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  23 in total

Review 1.  Pulmonary delivery of drugs for bone disorders.

Authors:  J S Patton
Journal:  Adv Drug Deliv Rev       Date:  2000-08-31       Impact factor: 15.470

2.  Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats.

Authors:  Valérie Codrons; Francis Vanderbist; Roger K Verbeeck; Mohammed Arras; Dominique Lison; Véronique Préat; Rita Vanbever
Journal:  J Pharm Sci       Date:  2003-05       Impact factor: 3.534

3.  Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34).

Authors:  A Pfützner; F Flacke; R Pohl; D Linkie; M Engelbach; R Woods; T Forst; J Beyer; S S Steiner
Journal:  Horm Metab Res       Date:  2003-05       Impact factor: 2.936

4.  Characterization of protein aggregation: the case of a therapeutic immunoglobulin.

Authors:  Barthélemy Demeule; M Jayne Lawrence; Alex F Drake; Robert Gurny; Tudor Arvinte
Journal:  Biochim Biophys Acta       Date:  2006-10-27

Review 5.  Particle engineering techniques for inhaled biopharmaceuticals.

Authors:  Sunday A Shoyele; Simon Cawthorne
Journal:  Adv Drug Deliv Rev       Date:  2006-08-12       Impact factor: 15.470

6.  Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats.

Authors:  S Kobayashi; S Kondo; K Juni
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

Review 7.  The economic and human costs of osteoporotic fracture.

Authors:  E Barrett-Connor
Journal:  Am J Med       Date:  1995-02-27       Impact factor: 4.965

8.  A comparison between the protection of LDH during freeze-thawing by PEG 6000 and Brij 35 at low concentrations.

Authors:  Anna Hillgren; Maggie Aldén
Journal:  Int J Pharm       Date:  2002-09-05       Impact factor: 5.875

Review 9.  Teriparatide: a review.

Authors:  Elaena Quattrocchi; Helen Kourlas
Journal:  Clin Ther       Date:  2004-06       Impact factor: 3.393

Review 10.  Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women.

Authors:  Armen H Tashjian; Bruce A Chabner
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

View more
  7 in total

Review 1.  New targets for intervention in the treatment of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Nat Rev Rheumatol       Date:  2011-09-20       Impact factor: 20.543

2.  Self-associated submicron IgG1 particles for pulmonary delivery: effects of non-ionic surfactants on size, shape, stability, and aerosol performance.

Authors:  Asha R Srinivasan; Sunday A Shoyele
Journal:  AAPS PharmSciTech       Date:  2012-12-20       Impact factor: 3.246

Review 3.  Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.

Authors:  Roland Baron; Eric Hesse
Journal:  J Clin Endocrinol Metab       Date:  2012-01-11       Impact factor: 5.958

4.  Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.

Authors:  Erin M Wilson; J Christopher Luft; Joseph M DeSimone
Journal:  Pharm Res       Date:  2018-08-23       Impact factor: 4.200

Review 5.  Bone anabolics in osteoporosis: Actuality and perspectives.

Authors:  Andrea Montagnani
Journal:  World J Orthop       Date:  2014-07-18

Review 6.  Assessment of sex specific endocrine disrupting effects in the prenatal and pre-pubertal rodent brain.

Authors:  Meghan E Rebuli; Heather B Patisaul
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-22       Impact factor: 4.292

7.  Influence of Parathyroid Hormone-Loaded PLGA Nanoparticles in Porous Scaffolds for Bone Regeneration.

Authors:  Piergiorgio Gentile; Vijay Kumar Nandagiri; Ritesh Pabari; Jacqueline Daly; Chiara Tonda-Turo; Gianluca Ciardelli; Zebunnissa Ramtoola
Journal:  Int J Mol Sci       Date:  2015-08-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.